F
Fredrik Eriksson
Researcher at Uppsala University
Publications - 16
Citations - 566
Fredrik Eriksson is an academic researcher from Uppsala University. The author has contributed to research in topics: Tumor microenvironment & Immunotherapy. The author has an hindex of 8, co-authored 15 publications receiving 437 citations.
Papers
More filters
Journal ArticleDOI
Age-Related Somatic Structural Changes in the Nuclear Genome of Human Blood Cells
Lars Forsberg,Chiara Rasi,Hamid Reza Razzaghian,Geeta Pakalapati,Lindsay L. Waite,Krista Stanton Thilbeault,Anna Ronowicz,Nathan E. Wineinger,Hemant K. Tiwari,Dorret I. Boomsma,Maxwell P. Westerman,Jennifer R. Harris,Robert Lyle,Magnus Essand,Fredrik Eriksson,Themistocles L. Assimes,Carlos Iribarren,Eric Strachan,Terrance P. O'Hanlon,Lisa G. Rider,Frederick W. Miller,Vilmantas Giedraitis,Lars Lannfelt,Martin Ingelsson,Arkadiusz Piotrowski,Nancy L. Pedersen,Devin Absher,Jan P. Dumanski +27 more
TL;DR: Age-related accumulation of copy-number variation in the nuclear genomes in vivo and frequency changes for both megabase- and kilobase-range variants are described and recurrent rearrangements uncovered here are candidates for common age-related defects in human blood cells.
Journal ArticleDOI
Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice.
Veronica Lindström,Therese Fagerqvist,Eva Nordström,Fredrik Eriksson,Anna Lord,Stina Tucker,Jessica Andersson,Malin Johannesson,Heinrich Schell,Philipp J. Kahle,Christer Möller,Pär Gellerfors,Joakim Bergström,Lars Lannfelt,Martin Ingelsson +14 more
TL;DR: Lower levels of pathogenic α-synuclein demonstrated, and a reduction of motor dysfunction in transgenic mice upon peripheral administration of mAb47 was indicated, suggest immunotherapy with antibodies targeting toxic α- synuclein species holds promise as a future disease-modifying treatment in Parkinson's disease and related disorders.
Journal ArticleDOI
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.
Linda C. Sandin,Fredrik Eriksson,Peter Ellmark,Angelica Loskog,Thomas H. Tötterman,Sara M. Mangsbo +5 more
TL;DR: This study confirms previous findings that local administration of low-dose anti- CTLA4 antibody generates sustained antitumor effects and provides rationale to devise ultrasound-guided intratumoral anti-CTLA4 antibodies injection regimens to treat patients with pancreatic adenocarcinoma and other types of solid tumors.
Journal ArticleDOI
DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer.
Fredrik Eriksson,Thomas H. Tötterman,Anna-Karin Maltais,Pavel Pisa,Pavel Pisa,Jeffrey Yachnin,Jeffrey Yachnin,Jeffrey Yachnin +7 more
TL;DR: Safety, clinical efficacy and immunogenicity of a DNA vaccine coding for rhesus prostate specific antigen (PSA) delivered by intradermal injection and skin electroporation and T-cell reactivity observed in patients with biochemical relapse of prostate cancer without macroscopic disease are tested.
Journal ArticleDOI
Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
Linda Söderberg,Malin Johannesson,Patrik Nygren,Hanna Laudon,Fredrik Eriksson,Gunilla Osswald,Christer Möller,Lars Lannfelt +7 more
TL;DR: This article characterized the binding properties of lecanemab, aducanumab, and gantenerumab to different Aβ species with inhibition ELISA, immunodepletion, and surface plasmon resonance.